Stereotaxis, Inc. Q1 2007 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2007. Stereotaxis, Inc. designs, manufactures, and markets the NIOBE magnetic navigation system, an advanced cardiology instrument control system used to guide catheters and guidewires during interventional procedures for arrhythmias and coronary artery disease. The company operates primarily in the U.S., Europe, and Asia.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Total Revenue | $9.16 million | $1.73 million |
| Gross Margin | $5.91 million (64.5%) | $0.50 million (28.9%) |
| Operating Loss | $(10.81) million | $(14.52) million |
| Net Loss | $(10.50) million | $(14.60) million |
| Cash and Equivalents | $46.44 million | $3.60 million (end of period) |
| Working Capital | $50.32 million | $40.38 million (Dec 31, 2006) |
| Debt (Current + Long-term) | $1.72 million | $1.97 million (Dec 31, 2006) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 429% year-over-year, driven by a jump in system deliveries from one unit in Q1 2006 to six units in Q1 2007. Systems revenue rose to $7.21 million from $0.98 million.
- Improved Margins: Gross margin expanded significantly to 64.5% from 28.9%, reflecting the higher mix of system sales.
- Reduced Losses: Net loss decreased by approximately 28% to $10.5 million, primarily due to higher revenue and a significant reduction in interest expense (down 86% to $80,000) following the amortization of warrant expenses in the prior year.
- Operating Expenses: Sales and marketing expenses increased 25% to $6.08 million due to expanded headcount. Research and development expenses decreased 7% to $5.69 million.
- Liquidity Position: Cash and cash equivalents grew from $15.2 million at year-end 2006 to $46.4 million, bolstered by a $20.1 million net proceeds from a common stock offering in March 2007 and the maturity of short-term investments.
Outlook, Risks, and Management Commentary
- Backlog: Purchase orders and commitments for the magnetic navigation system totaled approximately $49 million as of March 31, 2007. Management notes these are subject to contingencies and may be revised or cancelled.
- Capital Resources: The company amended its credit agreement in March 2007, increasing borrowing capacity to $25 million and extending the maturity to March 2009. The company expects negative cash flow from operations through 2007 and anticipates total operating expenses will increase approximately 15% over 2006 levels.
- Risks: Key risks include the need for additional financing if cash resources are depleted, foreign currency exchange fluctuations (a 10% Euro fluctuation could impact revenue by 2-3%), and the uncertainty of recognizing revenue from the current backlog.
- Accounting Updates: The company adopted FIN 48 (Accounting for Uncertainty in Income Taxes) effective January 1, 2007, with no significant impact on financial position. SFAS 159 (Fair Value Option) is pending adoption in 2008.
Investor Verification Checklist
- Verify the convertibility of the $49 million backlog into recognized revenue, noting the risk of order cancellations or delays.
- Monitor the burn rate of cash given the expectation of negative operating cash flow through 2007 and the reliance on equity financing.
- Review the impact of the increased sales and marketing spend on future revenue growth rates.
- Assess the company's compliance with the quick asset ratio covenant (1.75 to 1) under the amended credit agreement.
- Confirm the status of regulatory clearances and clinical trial progress for new product developments.